Recursion Pharmaceuticals, which combines artificial intelligence (AI), experimental biology, and automation to discover and develop drugs, has been given a $1.6m Phase 2 Small Business Innovation Research (SBIR) award from the National Institutes of Health (NIH) through the National Institute on Aging (NIA).
Clinical-stage biotechnology firm BioTime has signed an agreement to acquire the remaining stake in Asterias Biotherapeutics for an undisclosed sum.
US-based Brooklyn ImmunoTherapeutics, a newly formed company, has acquired the assets of IRX Therapeutics for an undisclosed price.
Shire has agreed to license exclusive worldwide rights to two rare cholestatic liver disease candidates, including the maralixibat oral inhibitor, to clinical-stage therapeutics company Mirum Pharmaceuticals.
Alexion Pharmaceuticals has wrapped up its previously announced acquisition of US-based clinical-stage biotechnology firm Syntimmune in a deal worth $1.2bn.
Gilead Sciences and Tango Therapeutics have entered into a global collaboration to discover, develop and commercialize a pipeline of targeted immuno-oncology treatments for cancer.
Terns Pharmaceuticals, a biopharma company focused on discovering and developing molecularly targeted, oral, small-molecule drugs for the treatment of NASH and cancer, has raised $80m through a Series B financing round.
Eli Lilly and Company (Lilly) and Dicerna Pharmaceuticals have signed a global licensing and research collaboration focused on the discovery, development and commercialization of new drugs in the areas of cardio-metabolic disease, neurodegeneration and pain.
Alexion Pharmaceuticals and Dicerna Pharmaceuticals have entered into a collaboration to discover and develop RNA interference (RNAi) therapies for complement-mediated diseases.
Stoke Therapeutics, a US-based biotechnology company focused on the development of drugs for severe genetic diseases, has raised $90m in a Series B financing round.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.